SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/CosmeticResearch peptide

Argireline

aka Acetyl Hexapeptide-3 · Acetyl Hexapeptide-8

Topical hexapeptide marketed as a 'Botox-like' expression-line softener.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Argireline is a SNAP-25-derived hexapeptide formulated into topical cosmetics for fine lines from repeated facial expression.

Source
  • Synthesized for cosmetic use
Forms
  • Topical cream and serum

Mechanism of action

Competes with SNAP-25 at the SNARE complex, modestly reducing neurotransmitter release at the neuromuscular junction in the skin.

Pathways
  • · SNARE complex inhibition
  • · Acetylcholine release reduction at neuromuscular junction

How it acts on the body

Argireline mimics the N-terminal end of SNAP-25, the SNARE protein cleaved by botulinum toxin. By competing for the same binding site it partially destabilizes the SNARE complex, modestly reducing acetylcholine release and the depth of fine expression lines.

The effect is far weaker than botulinum toxin and reverses quickly once application stops, but it is non-invasive and well-tolerated, which keeps it in popular use.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Acetylcholine release (local)Decreases
Localized neuromuscular junction effect only — no systemic hormonal impact.

Effects on the body

Decreases
Depth of expression lines with consistent use

Organ system effects

Skin

Reduced dynamic wrinkle depth.

Endocrine

No systemic endocrine effect.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Non-invasive alternative to neuromodulators
  • Generally well-tolerated

Potential side effects

Common
  • · Mild local irritation
Rare
  • · Allergic contact dermatitis
Serious
  • · None documented from topical use

Drug interactions

No notable interactions reported.

Pairing context

Often combined with
  • Daily sunscreen and retinoid
    Addresses static-aging contributors that Argireline does not.
Avoid combining with
  • Open wounds or active dermatitis on the application site
    Increased irritation and absorption.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.